In vitro activity of tigecycline (GAR-936) and other antimicrobials against tetracycline- and ciprofloxacin-resistant Campylobacter clinical isolates

International Journal of Antimicrobial Agents

Volumn 27, Issue 4, 2006, Pages 303-306

  Rodríguez Avial, Iciar ^a   Rodríguez Avial, Carmen ^a   López, Olga ^a   Culebras, Esther ^a   Picazo, Juan J ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Antimicrobial susceptibility; Campylobacter spp.; Tigecycline

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; CIPROFLOXACIN; CLINDAMYCIN; ERYTHROMYCIN; TETRACYCLINE; TIGECYCLINE;

AGAR GEL DIFFUSION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CAMPYLOBACTER; CONTROLLED STUDY; FECES ANALYSIS; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; CAMPYLOBACTER; CAMPYLOBACTER INFECTIONS; CIPROFLOXACIN; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FECES; HOSPITALS; HUMANS; INPATIENTS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; SPAIN; TETRACYCLINE RESISTANCE;

EID: 33645989201     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2005.11.016     Document Type: Article

References (31)

1. Boyanova L., Gergova G., Spassova Z., et al. Campylobacter infection in 682 Bulgarian patients with acute enterocolitis, inflammatory bowel disease, and other chronic intestinal diseases. Diagn Microbiol Infect Dis 49 (2004) 71-74
2. Engberg J., Aarestrup F.M., Taylor D.E., Gerner-Smidt P., and Nachamkin I. Quinolone and macrolide resistance in Campylobacter jejuni and C. coli: resistance mechanism and trends in human isolates. Emerg Infect Dis 7 (2001) 24-34
3. Hakanen A.J., Lehyopolku M., Siitonen A., Huovinen P., and Kotilainen P. Multidrug resistance in Campylobacter jejuni strains colleted from Finnish patients during 1995-2000. J Antimicrob Chemother 52 (2003) 1035-1039
4. Nachamkin I., Engberg J., and Aarestrup F.M. Diagnosis and antimicrobial susceptibility of Campylobacter spp. In: Nachamkin I., and Blaser M.J. (Eds). Campylobacter (2000), American Society for Microbiology, Washington, DC
5. Skirrow M.B., and Blaser M.J. Clinical aspects of Campylobacter infection. In: Nachamkin I., and Blaser M.J. (Eds). Campylobacter (2000), American Society for Microbiology, Washington, DC
6. Gaudreau C., and Gilberte H. Antimicrobial resistance of Campylobacter jejuni subsp. jejuni strains isolated from humans in 1998 to 2002 in Montréal, Canada. Antimicrob Agents Chemother 47 (2003) 2027-2029
7. Betriu C., Rodríguez-Avial I., Sánchez B.A., et al. In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain. Antimicrob Agents Chemother 46 (2002) 892-895
8. Gales A.C., and Jones R.N. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates. Diagn Microbiol Infect Dis 36 (2000) 19-36
9. Goldstein E.J., Citron D.M., Merriam C.V., Warren Y., and Tyrrell K. Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens. Antimicrob Agents Chemother 44 (2000) 2747-2751
10. Milatovic D.F., Schmitz J., Verhoef J., and Fluit A.C. Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates. Antimicrob Agents Chemother 47 (2003) 400-404
11. Petersen P.J., Jacobus N.V., Weiss W.J., Sum P.E., and Testa R.T. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamino derivative of minocycline (GAR-936). Antimicrob Agents Chemother 43 (1999) 738-744
12. Gaudreau C., and Gilbert H. Comparison of disc diffusion and agar dilution methods for antibiotic susceptibility testing of Campylobacter jejuni subsp. jejuni and Campylobacter coli. J Antimicrob Chemother 39 (1997) 707-712
13. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Fourteenth Informational Supplement, M100-S14. Wayne, PA: NCCLS; 2004.
14. Henwood C.J., Gatward T., Warner M., et al. Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936). J Antimicrob Chemother 49 (2002) 479-487
15. Jones R.N. Disk diffusion susceptibility test development for the new glycylcycline, GAR-936. Diagn Microbiol Infect Dis 35 (1999) 249-252
16. Deshpande L.M., Gales A.C., and Jones R.N. GAR-936 (9-t-butylglycylamido-minocycline) susceptibility test development for streptococci, Haemophilus influenzae and Neisseria gonorrhoeae: preliminary guidelines and interpretive criteria. Int J Antimicrob Agents 18 (2001) 29-35
17. Chatzipanagiotus S., Papavasileiou E., Lakumenta A., et al. Antimicrobial susceptibility patterns of Campylobacter jejuni strains isolated from hospitalized children in Athens, Greece. J Antimicrob Chemother 49 (2002) 803-805
18. Thwaites R.T., and Frost J.A. Drug resistance in Campylobacter jejuni, C. coli and C. lari isolates from humans in northwest England and Wales, 1997. J Clin Pathol 52 (1999) 812-814
19. Wagner J., Jabbusch M., Eisenblatther M., Hahn H., Wendt C., and Ignatius R. Susceptibilities of Campylobacter jejuni isolates from Germany to ciprofloxacin, moxifloxacin, erythromycin, clindamycin and tetracycline. Antimicrob Agents Chemother 47 (2003) 2358-2361
20. Fernández-Roblas R., Cabria F., Esteban J., López J.C., Gadea I., and Soriano F. In vitro activity of gemifloxacin (SB-265805) compared with 14 other antimicrobials against intestinal pathogens. J Antimicrob Chemother 46 (2000) 1023-1027
21. Ruiz F.J., Goni F., Marco F., et al. Increased resistance to quinolones in Campylobacter jejuni: a genetic analysis of gyrA gene mutations in quinolone-resistant clinical isolates. Microbiol Immunol 42 (1998) 223-226
22. Endtz H.P., Ruijs G.J., van Klingeren B., Jansen W.H., van der Reiden T., and Mouton R.P. Quinolone resistance in Campylobacter isolated from man and poultry following the introduction of fluoroquinolones in veterinary medicine. J Antimicrob Chemother 27 (1991) 199-208
23. Piddock L.J.V. Quinolone resistance and Campylobacter spp. J Antimicrob Chemother 36 (1995) 891-898
24. Garau J., Xercavins M., Rodríguez-Carballeira M., et al. Emergence and dissemination of quinolone-resistant Escherichia coli in the community. Antimicrob Agents Chemother 43 (1999) 2736-2741
25. Gaudreau C., and Gilberte H. Antimicrobial resistance of Campylobacter jejuni subsp. jejuni strains isolated from 1985 to 1997 in Quebec, Canada. Antimicrob Agents Chemother 42 (1998) 2106-2108
26. Gibreel A., Tracz D.M., Ninaka L., Ngo T.M., Connell S.R., and Taylor D.E. Incidence of antibiotic resistance in Campylobacter jejuni isolated in Alberta, Canada from 1999 to 2002, with special reference to tet(O)-mediated tetracycline resistance. Antimicrob Agents Chemother 48 (2004) 3442-3450
27. Li C.C., Chiu C.H., Wu J.L., Huang Y.C., and Lin T.Y. Antimicrobial susceptibilities of Campylobacter jejuni and coli by using E-test in Taiwan. Scand J Infect Dis 30 (1998) 39-42
28. Krausse R., and Ullmann U. In vitro activities of new fluoroquinolones against Campylobacter jejuni and Campylobacter coli isolates obtained from humans in 1980 to 1982 and 1997 to 2001. Antimicrob Agents Chemother 47 (2003) 2946-2950
29. Moore J.E., Crowe M., Heaney N., and Crothers E. Antibiotic resistance in Campylobacter spp. isolated from humans faeces (1980-2000) and foods (1997-2000) in Northern Ireland: an update. J Antimicrob Chemother 48 (2001) 455-457
30. Saenz Y., Zarazaga M., Lantero M., Gastañares M.J., Baquero F., and Torres C. Antibiotic resistance in Campylobacter strains isolated from animals, food, and humans in Spain in 1997-1998. Antimicrob Agents Chemother 44 (2000) 267-271
31. Tajada P., Gomez-Garces J., Alos J., Balas D., and Cogollos R. Antimicrobial susceptibilities of Campylobacter jejuni and Campylobacter coli to 12 beta-lactam agents and combinations with beta-lactamase inhibitors. Antimicrob Agents Chemother 40 (1996) 1924-1925